iX Biopharma Ltd. (SGX:42C)
0.0190
-0.0010 (-5.00%)
At close: Sep 19, 2025
iX Biopharma Revenue
In the fiscal year ending June 30, 2025, iX Biopharma had annual revenue of 7.77M SGD with 30.34% growth. iX Biopharma had revenue of 4.05M in the half year ending June 30, 2025, with 19.76% growth.
Revenue
7.77M
Revenue Growth
+30.34%
P/S Ratio
2.17
Revenue / Employee
184.93K
Employees
42
Market Cap
16.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 7.77M | 1.81M | 30.34% |
Jun 30, 2024 | 5.96M | 46.00K | 0.78% |
Jun 30, 2023 | 5.91M | -8.48M | -58.91% |
Jun 30, 2022 | 14.39M | 12.65M | 724.64% |
Jun 30, 2021 | 1.75M | 760.00K | 77.16% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DBS Group Holdings | 22.10B |
Oversea-Chinese Banking Corporation | 13.72B |
Singapore Telecommunications | 14.13B |
United Overseas Bank | 13.32B |
Singapore Technologies Engineering | 11.67B |
Jardine Matheson Holdings | 45.30B |
Singapore Airlines | 19.54B |
Hongkong Land Holdings | 2.27B |